

# Sale of Brooks Macdonald International

Released : 12 Sep 2024 07:04

RNS Number : 9234D  
Brooks Macdonald Group PLC  
12 September 2024

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THE INFORMATION COMMUNICATED IN THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 ("MAR"). THE EU MARKET ABUSE REGULATION ("EU MAR") CAME INTO EFFECT ON 3 JULY 2016 AND WAS ONSHORED INTO UK LAW ON 31 DECEMBER 2020 BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. CHANGES TO EU MAR WERE MADE BY THE MARKET ABUSE EXIT REGULATIONS 2019, TO MAKE SURE THAT THE ONSHORED LEGISLATION ("UK MAR") OPERATES EFFECTIVELY IN THE UK. THE EU TECHNICAL STANDARDS FOR EU MAR WERE ALSO ONSHORED INTO UK LAW ON 31 DECEMBER 2020 BY THE EU (WITHDRAWAL) ACT 2018 AND WERE AMENDED BY FCA 2019/45.

Brooks Macdonald Group plc  
For immediate release  
12 September 2024

**Brooks Macdonald Group plc**  
**Sale of Brooks Macdonald International**  
**to Canaccord Genuity Wealth Management Limited**

Brooks Macdonald Group plc ("Brooks Macdonald", the "Group" or the "Company") is pleased to announce that it has entered into a binding agreement with Canaccord Genuity Wealth (International) Holdings Limited ("Canaccord") to sell its wholly owned subsidiary, Brooks Macdonald Asset Management (International) Limited and its subsidiaries ("BMI"), for a total consideration of up to £50.85 million, including an initial consideration of £28 million payable in cash upon completion (the "Disposal"). Completion is expected by March 2025 subject to regulatory approvals.

The Disposal concludes the previously announced strategic review of the Group's international operations (the "Strategic Review").

**Transaction highlights & key terms**

- Initial consideration of £28 million, payable in cash on completion.
- Contingent consideration of up to £22.85 million, payable in cash two years post-completion. The contingent consideration will be dependent on the revenue performance of the BMI business.
- The proceeds of the Disposal will allow for focused investment in the Group's core proposition and will enhance its ability to capitalise on the structural opportunities in the UK, to grow organically and through targeted M&A.
- As of 30 June 2024, BMI had £2.3 billion of Funds under Management ("FUM"). In the financial year 2024, BMI delivered revenue of £19.9 million and £3.3 million of underlying profit before tax<sup>1</sup>.

**Background and rationale for the Disposal**

On 7 March 2024, the Group announced it had commenced the Strategic Review. Various options for BMI have been considered as part of this

review.

The Board has now concluded that the sale of BMI is in the best interests of the Group as it simplifies the Group's operations to focus on its core activities of high-quality investment management and financial planning within the UK. The proceeds of the Disposal will allow for focused investment in the Group's core proposition and will enhance its ability to capitalise on the structural opportunities in the UK, to grow organically and through targeted M&A.

In reaching an agreement with Canaccord, the Board has achieved an attractive result for the Company and its shareholders. The transaction also secures a highly credible future owner for BMI with a strong presence in the Crown Dependencies. The Group will work with Canaccord to ensure a smooth transition for existing BMI clients.

BMI will be acquired by Canaccord with an agreed level of regulatory capital, with any surplus paid for at completion.

The Group will incur £3-5m separation and transitional arrangement costs which will be treated as exceptional items in the current and the following financial year.

**Andrea Montague, CEO Designate & Chief Financial Officer of Brooks Macdonald, commented:**

"We are pleased to announce the sale of BMI to Canaccord as their presence and understanding of the local markets will provide a strong foundation for the future growth and development of the business. I would like to thank all our BMI colleagues for their commitment to their clients and professionalism. We wish them all the best for the future."

**David Esfandi, Chief Executive Officer of Canaccord Genuity Wealth Management, commented:**

"Brooks Macdonald International is a quality business and an excellent strategic fit for our international division. This is a mutually beneficial transaction that will cement Canaccord's position as a fully-fledged integrated wealth manager. Both firms are well-established across the Crown Dependencies, and BMI will also add significant financial planning expertise in our international business. Canaccord has a robust and scalable operating platform with a proven track record of successfully integrating businesses, and we anticipate a smooth process for BMI in 2025."

Brooks Macdonald is being advised by Raymond James Financial International Limited, and Travers Smith LLP as legal adviser, in relation to the sale of BMI.

**Enquiries:**

**Brooks Macdonald Group plc**

Andrea Montague, CEO Designate & Chief Financial Officer  
Alick Mackay, Strategy & Corporate Development Director

via Raymonds James

**Raymond James (Financial Adviser to the Company)**

Edward Griffin / Jack Wills

+44 (0) 20 3798 5700

**Singer Capital Markets Advisory LLP**

**(Nominated Adviser and Joint Broker)**

Charles Leigh-Pemberton / James Moat

+44 (0) 20 7496 3000

**Investec Bank plc (Joint Broker)**

Chris Baird / David Anderson

+44 (0) 20 7597 4000

**FTI (Media Enquiries)**

Edward Berry / Katherine Bell

[Brooksmacdonald@fticonsulting.com](mailto:Brooksmacdonald@fticonsulting.com)

07703 330199 / 07976 870961

**About Brooks Macdonald**

Brooks Macdonald Group plc, through its various subsidiaries, provides leading wealth management services in the UK and internationally. The Group, which was founded in 1991 and began trading on AIM in 2005, had discretionary FUM of £18.0 billion as of 30 June 2024.

Brooks Macdonald offers outsourced discretionary investment management for intermediaries and advice-led integrated wealth management for private clients. The Group also acts as fund manager to a range of onshore and international funds.

The Group has a strong local presence across the UK.

#### About BMI

BMI provides its services to international clients and intermediaries through its Crown Dependencies based investment management, financial planning, and fund management subsidiaries, Brooks Macdonald Asset Management (International) Limited and Brooks Macdonald International Fund Managers Limited. BMI has offices in Jersey, Guernsey and the Isle of Man with the majority of its 57 employees located in the Jersey office.

As of 30 June 2024, BMI had £2.3 billion of FUM with annual revenue of £19.9 million and £3.3 million of underlying profit before tax<sup>[1]</sup>. This is after accounting for £4.3 million of central cost recharges from Group functions which will not transfer as part of the Disposal. BMI had net assets of £29.8m as of 30 June 2024.

#### Cautionary statements

This Announcement may contain, and the Company may make verbal statements containing "forward-looking statements" with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives, and results. Forward-looking statements sometimes use words such as "aim", "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "seek", "may", "could", "outlook" or other words of similar meaning. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company. As a result, the actual future financial condition, performance, and results of the Company may differ materially from the plans, goals and expectations set forth in any forward-looking statements. Any forward-looking statements made in this Announcement by or on behalf of the Company speak only as of the date they are made.

The information contained in this Announcement is subject to change without notice and except as required by applicable law or regulation (including to meet the requirements of the AIM Rules, MAR, the Prospectus Rules and/or FSMA), the Company expressly disclaims any obligation or undertaking to publish any updates or revisions to any forward-looking statements contained in this Announcement to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statements are based. Statements contained in this Announcement regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Announcement.

No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future years would necessarily match or exceed the historical published earnings per share of the Company.

---

1] BMI's underlying PBT represents a statutory loss before tax of £0.3m for the year ended 30 June 2024 at the consolidated Group level, excluding amortisation of client relationships, organisational restructure costs, and consolidation adjustments

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DISEASNAFEKLEEA